R
Reinhard Marks
Researcher at University of Freiburg
Publications - 111
Citations - 2701
Reinhard Marks is an academic researcher from University of Freiburg. The author has contributed to research in topics: Transplantation & Medicine. The author has an hindex of 23, co-authored 91 publications receiving 2191 citations. Previous affiliations of Reinhard Marks include University Medical Center Freiburg.
Papers
More filters
Journal ArticleDOI
Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey
Robert Zeiser,Andreas Burchert,Claudia Lengerke,Mareike Verbeek,Kristina Maas-Bauer,S K Metzelder,Silvia Spoerl,Markus Ditschkowski,Matyas Ecsedi,Katja Sockel,Francis Ayuk,Salem Ajib,F.S. de Fontbrune,Il-Kang Na,Livius Penter,Udo Holtick,Dominik Wolf,Esther Schuler,Everett Meyer,Petya Apostolova,Hartmut Bertz,Reinhard Marks,Michael Lübbert,Ralph Wäsch,Christoph Scheid,Friedrich Stölzel,Rainer Ordemann,Gesine Bug,Guido Kobbe,Robert S. Negrin,Mats Brune,Alexandros Spyridonidis,Annette Schmitt-Gräff,W.J.F.M. van der Velden,Gerwin Huls,Stephan Mielke,G. U. Grigoleit,Jürgen Kuball,Ryan Flynn,Gabriele Ihorst,Jing Du,Bruce R. Blazar,Renate Arnold,Kröger N,Jakob Passweg,Jörg Halter,Gérard Socié,Dietrich W. Beelen,Christian Peschel,Andreas Neubauer,Jürgen Finke,Justus Duyster,N von Bubnoff +52 more
TL;DR: Ruxolitinib may constitute a promising new treatment option for SR-aGVHD and SR-cGVHD that should be validated in a prospective trial.
Journal ArticleDOI
High-Dose Chemotherapy With Autologous Stem-Cell Transplantation and Hyperfractionated Radiotherapy As First-Line Treatment of Primary CNS Lymphoma
Gerald Illerhaus,Reinhard Marks,Gabriele Ihorst,Roland Guttenberger,Christoph B. Ostertag,Günther Derigs,Norbert Frickhofen,Friedrich Feuerhake,Benedikt Volk,Jürgen Finke +9 more
TL;DR: Sequential systemic methotrexate and AraC and thiotepa followed by HDT plus ASCT and hyperfractionated WBRT is very effective with little toxicity as initial therapy for PCNSL.
Journal ArticleDOI
Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment
Gerhard Zugmaier,Nicola Gökbuget,Matthias Klinger,Andreas Viardot,Matthias Stelljes,Svenja Neumann,Heinz-A. Horst,Reinhard Marks,Christoph Faul,H. Diedrich,Albrecht Reichle,Monika Brüggemann,Chris Holland,Margit Schmidt,Hermann Einsele,Ralf C. Bargou,Max S. Topp +16 more
TL;DR: This long-term follow-up analysis evaluated overall survival (OS) and relapse-free survival (RFS) in a phase 2 study of the bispecific T-cell engager antibody construct blinatumomab in 36 adults with relapsed/refractory B-precursor acute lymphoblastic leukemia (ALL).
Journal ArticleDOI
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.
Viola Poeschel,Gerhard Held,Marita Ziepert,Mathias Witzens-Harig,Harald Holte,Lorenz Thurner,Peter Borchmann,Andreas Viardot,Martin Soekler,Ulrich Keller,Christian Schmidt,Lorenz Truemper,Rolf Mahlberg,Reinhard Marks,Heinz-Gert Hoeffkes,Bernd Metzner,Judith Dierlamm,Norbert Frickhofen,Mathias Haenel,Andreas Neubauer,Michael Kneba,Francesco Merli,Alessandra Tucci,Peter de Nully Brown,Massimo Federico,Eva Lengfelder,Alice Di Rocco,Ralf Ulrich Trappe,Andreas Rosenwald,Christian Berdel,Martin Maisenhoelder,Ofer Shpilberg,Josif Amam,Konstantinos Christofyllakis,Frank Hartmann,Niels Murawski,Stephan Stilgenbauer,Maike Nickelsen,Gerald Wulf,Bertram Glass,Norbert Schmitz,Bettina Altmann,Markus Loeffler,Michael Pfreundschuh,Flyer Trial Investigators,German Lymphoma Alliance +45 more
TL;DR: The FLYER trial assessed whether four cycles of CHOP plus six applications of rituximab are non-inferior to six cycles of R-CHOP in a population of patients with B-cell non-Hodgkin lymphoma with favourable prognosis, demonstrating the non- inferiority of the four-cycles regimen.
Journal ArticleDOI
Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial
Marek Trněný,Thierry Lamy,Jan Walewski,David Belada,Jiri Mayer,John Radford,Wojciech Jurczak,Franck Morschhauser,Julia Alexeeva,Simon Rule,Boris V. Afanasyev,K. D. Kaplanov,Antoine Thyss,Alexej Kuzmin,Sergey Voloshin,Kazimierz Kuliczkowski,Agnieszka Giza,Noel Milpied,Caterina Stelitano,Reinhard Marks,Lorenz Trümper,Tsvetan Biyukov,Meera Patturajan,Marie Laure Casadebaig Bravo,Luca Arcaini +24 more
TL;DR: Patients with relapsed or refractory mantle cell lymphoma ineligible for intensive chemotherapy or stem-cell transplantation have longer progression-free survival, with a manageable safety profile when treated with lenalidomide compared with monotherapy investigator's choice options.